Erste Group analysts upgraded Eli Lilly stock from Hold to Buy, citing a robust product demand and a promising pipeline of potential successes. The analysts highlighted the pharmaceutical company's ...

Eli Lilly Chief Corporate Brand Officer Lina Polimeni on how the brand differentiates itself in the crowded pharma market, ...

Eli Lilly (LLY) investors should expect fireworks this week as the pharma giant prepares to drop its bombshell Q4 2024 ...

We recently compiled a list of the Jim Cramer Discusses These 10 Stocks & Comments On OpenAI’s Valuation. In this article, we ...

Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The firm’s revenue was up 20.4% compared to the same quarter last year. During the same period in the prior ...

Shares of Eli Lilly & Co. were headed for their worst day in ... MarketWatch's deputy investing and corporate news editor and is based in New York. You can follow him on Twitter @TomiKilgore.

Shelby Knowles / Bloomberg via Getty Images Eli Lilly's Zepbound can be covered by Medicare Part D plans after the FDA approved the drug as a treatment for sleep apnea last month. Weight loss ...

Indianapolis: Eli Lilly and Company has ... gastroenterology and nutrition, co-director, Susan and Leonard Feinstein IBD Clinical Center, Mount Sinai Kravis Children's Hospital, Icahn School of ...

Eli Lilly pre-announced a sizable Q4 2024 revenue miss headed into the big J.P. Morgan healthcare investor conference, but the biopharma reported massive growth. A lot of the quarterly ...

Shares of Eli Lilly have been falling in recent months, but that could spell opportunity. Investors appear to be concerned that a new government could impact its growth potential. The business is ...

Eli Lilly announced preliminary fourth-quarter revenue of roughly $13.5 billion, or $400 million below the low end of its guidance, driven by slower-than-expected US market growth and lower ...

Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Evan Seigerman from BMO Capital maintained a Buy rating on the ...